Systematic review of medical treatment in melanoma: current status and future prospects, The Oncologist, vol.16, issue.1, pp.5-24, 2011. ,
Recommandations/ Traitement des patients atteints de mélanome stade III inopérable ou de stade IV / Société Française de Dermatologie, 2017. ,
Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, vol.372, issue.4, pp.320-350, 2015. ,
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006), Lancet Lond Engl, vol.390, pp.1853-62, 2017. ,
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. The Oncologist, vol.21, pp.1230-1270, 2016. ,
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, Ann Oncol, vol.28, issue.7, pp.1605-1616, 2017. ,
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1, Clin Cancer Res Off J Am Assoc Cancer Res, vol.23, issue.8, pp.1920-1928, 201715. ,
Immunothérapie des cancers au troisième millénaire, 2014. ,
Classification of current anticancer immunotherapies, Oncotarget, vol.5, issue.24, pp.12472-508, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-01142463
Les cellules dendritiques ,
Immunité adaptative : lymphocytes T régulateurs et notion de tolérance ,
Immunité adaptative : activation et polarisation des lymphoctes T ,
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, vol.331, issue.6024, pp.1565-70, 2011. ,
Immunothérapie : les checkpoints, Rev Mal Respir Actual, vol.8, issue.5, pp.387-98, 2016. ,
Cancer immunoediting: from immunosurveillance to tumor escape, Nat Immunol, vol.3, issue.11, pp.991-999, 2002. ,
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy, J Hematol OncolJ Hematol Oncol, vol.9, issue.1, p.47, 201627. ,
Monitoring immune-checkpoint blockade: response evaluation and biomarker development, Nat Rev Clin Oncol, vol.14, issue.11, pp.655-68, 2017. ,
Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer, N Engl J Med, vol.366, issue.26, pp.2443-54, 2012. ,
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy, Mol Cancer Ther, vol.14, issue.4, pp.847-56, 2015. ,
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy, Nat Rev Cancer, vol.16, issue.5, pp.275-87, 2016. ,
PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, issue.7528, pp.568-71, 2014. ,
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, vol.515, issue.7528, pp.563-570, 2014. ,
Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma, N Engl J Med, vol.373, issue.1, pp.23-34, 2015. ,
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.375, issue.19, pp.1823-1856, 201610. ,
, Pembrolizumab (KEYTRUDA) checkpoint inhibitor, 2016.
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma, J Clin Invest, vol.126, issue.9, pp.3447-52, 2016. ,
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma, Clin Cancer Res Off J Am Assoc Cancer Res, vol.23, issue.17, pp.5024-5057, 2017. ,
Biomarqueurs prédictifs de réponse aux inhibiteurs de points de contrôle immuns, Bull Cancer, 2018. ,
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma, Cell, vol.165, issue.1, pp.35-44, 2016. ,
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, N Engl J Med, vol.372, issue.26, pp.2509-2529, 2015. ,
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response, Nature, vol.545, issue.7652, pp.60-65, 2017. ,
Highdimensional single-cell analysis predicts response to anti-PD-1 immunotherapy, Nat Med, vol.24, issue.2, pp.144-53, 2018. ,
Critères de la réponse tumorale en imagerie : RECIST, mRECIST, Cheson. Datarevues22115706v95i7-8S2211570614002859, 2014. ,
Transforming growth factor-beta "reprograms" the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset, Nat Immunol, vol.9, issue.12, pp.1341-1347, 2008. ,
IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells, Nat Immunol, vol.9, issue.12, pp.1347-55, 2008. ,
Th9 cells promote antitumor immune responses in vivo, J Clin Invest, vol.122, issue.11, pp.4160-71, 2012. ,
Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients, Oncoimmunology, vol.5, issue.12, p.1248327, 2016. ,
CD4+CD25+CD127-assessment as a surrogate phenotype for FOXP3+ regulatory T cells in HIV-1 infected viremic and aviremic subjects, Cytometry B Clin Cytom, vol.84, issue.1, pp.50-54, 2013. ,
,
,
,
, regulatory T cells in peripheral blood of HIV
, Za Zhi Chin J Cell Mol Immunol, vol.28, issue.11, pp.1188-91, 2012.
The immune contexture in human tumours: impact on clinical outcome, Nat Rev Cancer, vol.15, issue.4, pp.298-306, 2012. ,
Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells, Immunol Cell Biol, vol.96, issue.1, pp.21-33, 2018. ,
Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.27, issue.2, pp.186-92, 2009. ,
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. Vaccines, vol.4, 2016. ,
Regulatory T-cell heterogeneity and the cancer immune response, Clin Transl Immunol, vol.6, issue.9, p.154, 2017. ,
Regulatory T cells in the immunotherapy of melanoma, Tumour Biol J Int Soc Oncodevelopmental Biol Med, vol.37, issue.1, pp.77-85, 2016. ,
Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells, J Immunol Baltim Md, vol.173, issue.2, pp.1444-53, 1950. ,
CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens, J Immunother Hagerstown Md, vol.26, issue.1, pp.85-93, 1997. ,
Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood, Cancer Immunol Immunother CII, vol.57, issue.12, pp.1795-805, 2008. ,
Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma, Oncol Rep, vol.18, issue.5, pp.1115-1137, 2007. ,
Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma, Cancer, vol.116, issue.9, p.78, 2010. ,
Increased survival from stage IV melanoma associated with fewer regulatory T Cells, J Surg Res, vol.154, issue.1, pp.13-20, 2009. ,
An Atlas of Human Regulatory T Helper-like Cells Reveals Features of Th2-like Tregs that Support a Tumorigenic Environment, Cell Rep, vol.20, issue.3, pp.757-70, 2017. ,
Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment, Oncotarget, vol.16, issue.20, pp.33159-71, 2017. ,
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells, Cancer Immunol Res, vol.1, issue.1, pp.32-42, 2013. ,
Immuno-régulation par les lymphocytes T régulateurs, 2015. ,
Fcdependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma, J Exp Med, vol.210, issue.9, pp.1695-710, 2013. ,
Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?, Cell Biosci, vol.8, p.30, 2018. ,
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma, Cancer Immunol Immunother CII, vol.63, issue.7, pp.675-83, 2014. ,
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors, Proc Natl Acad Sci, vol.107, issue.9, pp.4275-80, 2010. ,
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells, Int Immunol, vol.21, issue.9, pp.1065-77, 2009. ,